We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis.
- Authors
del Carpio, Luis P.; Algarra, María Asunción; Sabaté‐Llobera, Aida; Rodriguez‐Vida, Alejo; Rossi‐Seoane, Susana; Ruiz, Sandra; Leiva, David; Ramos, Emilio; Lladò, Laura; Lorenzo, Daniel; Gutierrez, Cristina; Cortes‐Romera, Montserrat; Caminal, Josep M.; Piulats, Josep M.
- Abstract
Background: Uveal melanoma metastasizes to the liver. We aimed to explore the metabolic activity of liver metastases (LM) as a biomarker for survival. Methods: We analyzed newly diagnosed patients with metastatic UM (MUM) with LM detected by liver‐directed imaging and had undergone a PET/CT at diagnosis. Findings: 51 patients were identified between 2004 and 2019. Median age was 62 years, 41% male and 22% ECOG ≥1. LDH, ALP, and GGT were elevated in 49%, 37%, and 57% of patients. Median LM SUVmax was 8.5 (3–42.2). Same size lesions presented a wide range of metabolic activity. Median OS was 17.3 m (95% CI:10.6–23.9). Patients with SUVmax ≥8.5 had an OS of 9.4 m (95% CI:6.4–12.3), whereas patients with SUVmax <8.5 had an OS of 38.4 m (95% CI:21.4–55.5; p < 0.0001, HR = 2.9). We observed similar results when studying M1a disease separately. Multivariate analysis showed SUVmax as an independent prognostic factor for the whole population and those with M1a disease. Interpretation: Increased metabolic activity of LM seems to be an independent predictor of survival. MUM is a heterogeneous disease and metabolic activity probably reflects a different intrinsic behavior.
- Subjects
LIVER metastasis; UVEA cancer; MELANOMA; METASTASIS; GLUCOSE; PROGNOSIS
- Publication
Cancer Medicine, 2023, Vol 12, Issue 13, p14062
- ISSN
2045-7634
- Publication type
Article
- DOI
10.1002/cam4.6058